Free tool
FAERS Monitor: Mycapssa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208232 or its brand name (Mycapssa, Octreotide Acetate). Reports on generic versions are filed under their own applications.
Reports
5,732
Serious
4,922
86% of reports
Hospitalization
2,370
Death reported
920
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use753
- drug ineffective718
- diarrhoea550
- death393
- nausea373
- fatigue325
- malignant neoplasm progression253
- abdominal pain232
- vomiting219
- weight decreased187
- dyspnoea186
- drug ineffective for unapproved indication185
- pain180
- product use in unapproved indication179
- asthenia169
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 23 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 9 |
| 2011 | 16 |
| 2012 | 70 |
| 2013 | 105 |
| 2014 | 143 |
| 2015 | 192 |
| 2016 | 225 |
| 2017 | 343 |
| 2018 | 380 |
| 2019 | 347 |
| 2020 | 333 |
| 2021 | 572 |
| 2022 | 630 |
| 2023 | 600 |
| 2024 | 542 |
| 2025 | 682 |
| 2026 | 494 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,427 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug ineffective for unapproved indicationSignal | 185 | 12.4 | 10.8 | 1,928 |
| malignant neoplasm progressionSignal | 253 | 9.1 | 8.1 | 1,817 |
| abdominal painSignal | 232 | 3.7 | 3.2 | 451 |
| off label useSignal | 753 | 3.2 | 3.0 | 1,155 |
| diarrhoeaSignal | 550 | 3.1 | 2.9 | 819 |
| product use in unapproved indicationSignal | 179 | 2.7 | 2.3 | 185 |
| weight decreasedSignal | 187 | 2.5 | 2.1 | 162 |
| drug ineffective | 718 | 2.0 | 1.9 | 382 |
| nausea | 373 | 1.7 | 1.6 | 118 |
| vomiting | 219 | 1.7 | 1.5 | 65 |
| death | 393 | 1.7 | 1.5 | 110 |
| asthenia | 169 | 1.6 | 1.4 | 43 |
| fatigue | 325 | 1.5 | 1.4 | 62 |
| dyspnoea | 186 | 1.2 | 1.0 | 6 |
| pain | 180 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.